
# Pharmacology Knowledge Base

## Pharmacokinetics and Pharmacodynamics

### Pharmacokinetics (ADME)
- **Absorption**: Drug uptake from administration site
  - Bioavailability: Fraction reaching systemic circulation
  - First-pass metabolism: Hepatic metabolism before systemic circulation
  - Routes: Oral, IV, IM, SC, topical, inhalation

- **Distribution**: Drug movement throughout body
  - Volume of distribution (Vd): Apparent volume drug distributes into
  - Protein binding: Albumin, alpha-1-acid glycoprotein
  - Blood-brain barrier: Lipophilic drugs cross more easily

- **Metabolism**: Drug biotransformation
  - Phase I: Oxidation, reduction, hydrolysis (CYP450 enzymes)
  - Phase II: Conjugation reactions (glucuronidation, sulfation)
  - Hepatic clearance: Liver's ability to eliminate drug

- **Excretion**: Drug elimination from body
  - Renal clearance: Glomerular filtration, tubular secretion/reabsorption
  - Half-life: Time for drug concentration to decrease by 50%
  - Steady state: Achieved after 5 half-lives

### Pharmacodynamics
- **Receptor Theory**: Drug-receptor interactions
- **Dose-Response Relationships**: ED50, therapeutic window
- **Agonists**: Activate receptors (full, partial)
- **Antagonists**: Block receptors (competitive, non-competitive)
- **Tolerance**: Decreased response with repeated exposure
- **Dependence**: Physical/psychological need for drug

## Cardiovascular Pharmacology

### Antihypertensive Agents
- **ACE Inhibitors**: Lisinopril, enalapril
  - Mechanism: Block angiotensin-converting enzyme
  - Side effects: Dry cough, hyperkalemia, angioedema
  - Contraindications: Pregnancy, bilateral renal artery stenosis

- **ARBs**: Losartan, valsartan
  - Mechanism: Block angiotensin II receptors
  - Advantages: No cough, similar efficacy to ACE inhibitors

- **Calcium Channel Blockers**: Amlodipine, diltiazem, verapamil
  - Dihydropyridines: Peripheral vasodilation
  - Non-dihydropyridines: Cardiac effects, AV node blockade

- **Beta-blockers**: Metoprolol, atenolol, propranolol
  - Selective (β1): Cardioselective
  - Non-selective (β1/β2): Bronchospasm risk
  - Contraindications: Asthma, severe heart failure

### Anticoagulants and Antiplatelets
- **Warfarin**: Vitamin K antagonist
  - Monitoring: INR (International Normalized Ratio)
  - Reversal: Vitamin K, fresh frozen plasma, prothrombin complex concentrate
  - Drug interactions: CYP2C9, VKORC1 polymorphisms

- **Heparin**: Activates antithrombin III
  - Unfractionated: IV, monitored by aPTT
  - Low molecular weight: SC, predictable dosing
  - Reversal: Protamine sulfate

- **DOACs**: Direct oral anticoagulants
  - Dabigatran: Direct thrombin inhibitor
  - Rivaroxaban, apixaban: Factor Xa inhibitors
  - Advantages: Fixed dosing, fewer interactions

- **Antiplatelets**: Aspirin, clopidogrel, ticagrelor
  - Aspirin: Irreversible COX-1 inhibition
  - P2Y12 inhibitors: ADP receptor blockade
  - Dual antiplatelet therapy: Post-PCI, ACS

## Central Nervous System Pharmacology

### Antidepressants
- **SSRIs**: Sertraline, fluoxetine, escitalopram
  - Mechanism: Selective serotonin reuptake inhibition
  - Side effects: GI upset, sexual dysfunction, serotonin syndrome
  - Discontinuation: Gradual taper to avoid withdrawal

- **SNRIs**: Venlafaxine, duloxetine
  - Mechanism: Serotonin and norepinephrine reuptake inhibition
  - Indications: Depression, anxiety, neuropathic pain

- **Tricyclics**: Amitriptyline, nortriptyline
  - Mechanism: Multiple neurotransmitter reuptake inhibition
  - Side effects: Anticholinergic, sedation, cardiac toxicity
  - Overdose: QRS widening, sodium bicarbonate treatment

### Antiepileptics
- **Phenytoin**: Sodium channel blocker
  - Monitoring: Serum levels, CBC, liver function
  - Side effects: Gingival hyperplasia, hirsutism, ataxia
  - Zero-order kinetics: Small dose changes cause large level changes

- **Carbamazepine**: Sodium channel blocker
  - Indications: Focal seizures, trigeminal neuralgia
  - Side effects: Diplopia, ataxia, hyponatremia
  - Drug interactions: CYP3A4 inducer

- **Valproic Acid**: Multiple mechanisms
  - Broad spectrum: Generalized and focal seizures
  - Side effects: Weight gain, hair loss, teratogenicity
  - Monitoring: Liver function, platelet count

### Opioid Analgesics
- **Morphine**: Gold standard opioid
  - Metabolism: Glucuronidation, active metabolites
  - Side effects: Respiratory depression, constipation, tolerance

- **Fentanyl**: Synthetic opioid, high potency
  - Routes: IV, transdermal, sublingual
  - Rapid onset, short duration

- **Oxycodone**: Semi-synthetic, oral bioavailability
- **Tramadol**: Weak opioid, serotonin/norepinephrine reuptake inhibition

## Antimicrobial Pharmacology

### Beta-lactam Antibiotics
- **Penicillins**: Penicillin G, amoxicillin, piperacillin
  - Mechanism: Cell wall synthesis inhibition
  - Resistance: Beta-lactamase production
  - Allergies: Cross-reactivity with cephalosporins (low)

- **Cephalosporins**: Cephalexin, ceftriaxone, ceftaroline
  - Generations: 1st (gram-positive) to 5th (MRSA)
  - Side effects: GI upset, C. difficile colitis

- **Carbapenems**: Imipenem, meropenem, ertapenem
  - Broad spectrum: Gram-positive, gram-negative, anaerobes
  - Reserved for severe infections, carbapenem resistance

### Fluoroquinolones
- **Ciprofloxacin, Levofloxacin**: DNA gyrase inhibition
- **Spectrum**: Gram-negative, atypical organisms
- **Side effects**: Tendon rupture, QT prolongation, C. difficile
- **Resistance**: Increasing, especially in gram-negatives

### Macrolides
- **Azithromycin, Clarithromycin**: Protein synthesis inhibition
- **Spectrum**: Gram-positive, atypicals (Mycoplasma, Chlamydia)
- **Side effects**: GI upset, QT prolongation
- **Drug interactions**: CYP3A4 inhibition (clarithromycin)

## Endocrine Pharmacology

### Diabetes Medications
- **Insulin**: Rapid, short, intermediate, long-acting
  - Types: Regular, NPH, glargine, detemir, degludec
  - Routes: SC, IV (regular insulin only)
  - Side effects: Hypoglycemia, weight gain, lipodystrophy

- **Metformin**: Biguanide, first-line type 2 diabetes
  - Mechanism: Decreased hepatic glucose production
  - Side effects: GI upset, lactic acidosis (rare)
  - Contraindications: Renal impairment, contrast exposure

- **Sulfonylureas**: Glyburide, glipizide
  - Mechanism: Insulin secretion stimulation
  - Side effects: Hypoglycemia, weight gain

- **SGLT2 Inhibitors**: Empagliflozin, canagliflozin
  - Mechanism: Glucose reabsorption inhibition
  - Benefits: Weight loss, cardiovascular protection
  - Side effects: UTIs, DKA, amputation risk

### Thyroid Medications
- **Levothyroxine**: Synthetic T4, hypothyroidism treatment
  - Dosing: Weight-based, TSH monitoring
  - Interactions: Iron, calcium, coffee affect absorption

- **Methimazole**: Antithyroid, hyperthyroidism treatment
  - Mechanism: Thyroid hormone synthesis inhibition
  - Side effects: Agranulocytosis, hepatotoxicity

## Drug Interactions and Safety

### Cytochrome P450 System
- **Major Enzymes**: CYP3A4, CYP2D6, CYP2C9, CYP2C19
- **Inducers**: Phenytoin, carbamazepine, rifampin
- **Inhibitors**: Ketoconazole, erythromycin, grapefruit juice
- **Clinical Significance**: Altered drug levels, efficacy, toxicity

### Adverse Drug Reactions
- **Type A**: Dose-dependent, predictable (80% of ADRs)
- **Type B**: Dose-independent, unpredictable (allergic reactions)
- **Monitoring**: Therapeutic drug monitoring, laboratory values
- **Reporting**: FDA MedWatch, pharmacovigilance

### Special Populations
- **Pediatric**: Weight-based dosing, developmental considerations
- **Geriatric**: Polypharmacy, altered pharmacokinetics
- **Pregnancy**: FDA categories, teratogenicity risk
- **Renal Impairment**: Dose adjustments, nephrotoxicity
- **Hepatic Impairment**: Metabolism alterations, hepatotoxicity
